AspenBio Pharma, Inc. company was founded in 2000 and is based in Castle Rock, Colorado. AspenBio Pharma, Inc. (AspenBio) is a biotechnology company engaged in the discovery, development, manufacture, and licensing or marketing of products. The Company is primarily focused on advancing towards commercialization its blood-based human diagnostic test, AppyScore to aid in the diagnosis of human appendicitis and several reproduction drugs for use in high value animals. AppyScore is a blood-based test to the aid in diagnosis of appendicitis. AppyScore measures the abundance of MRP 8/14, an inflammation biomarker, which AspenBio has identified to be elevated in acute appendicitis and demonstrates a correlation to the severity of the disease. In December 2008, the Company completed an 800 patient pivotal clinical trial for AppyScore. Products in its pipeline consist of product candidates in various stages of clinical and pre-clinical development.

MediciNova, Inc. company was founded in 2000 and is headquartered in San Diego, California. MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs principally in the United States. The company's development pipeline includes programs that are in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, interstitial cystitis, solid tumor cancers, generalized anxiety disorder/insomnia, preterm labor, and urinary incontinence. Its principal product development programs consist of MN-221, which is in Phase II clinical trial for the treatment of acute exacerbations of asthma; and MN-166 that has completed Phase II clinical trial for the treatment of multiple sclerosis. The company's other product development programs include MN-001, which completed Phase II/III clinical trial for the treatment of interstitial cystitis and an oral dosing formulation prototype for the treatment of bronchial asthma; MN-029 that completed second Phase I clinical trial for the treatment of solid tumors; MN-305, which completed a Phase II/III clinical trial for the treatment of generalized anxiety disorder and a Phase II clinical trial for the treatment of insomnia; MN-221 that completed a Phase I clinical trial for the treatment of preterm labor; and MN-246, a Phase I clinical trial completed product for the treatment of urinary incontinence. Its preclinical development products comprise MN-447 and MN-462 for the treatment of thrombotic disorders.

Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Our lead product candidate is Silenor® (doxepin) for the treatment of insomnia. Silenor is a sleep-specific, low-dose (3mg and 6mg), oral tablet formulation of doxepin that is patent-protected for use in insomnia. In contrast to higher-dose doxepin, Silenor is a potent antagonist that appears to selectively block histamine at the H1 receptor without a clinically relevant impact on other neurotransmitter systems. Doxepin at higher doses has been associated with a range of pharmacologic side effects that include anticholenerigic effects (dry mouth, constipation, etc.) and weight gain. In clinical trials, patients taking Silenor generally did not exhibit the side effects associated with higher doses of doxepin.

The German drug company -- seller of popular over-the-counter remedies Zantac and Dulcolax, as well as prescription Flomax for enlarged prostate -- makes a host of prescription and OTC products, not to mention fine chemicals and pet medications. Its prescription drugs include treatments for respiratory ailments, hypertension, HIV, and depression. Boehringer also offers cold, gastrointestinal, and pain remedies, as well as vaccines, drugs, and nutritionals for farm animals and pets. The company operates worldwide. The founding Boehringer family controls the company through parent company C.H. Boehringer Sohn.

Metabasis Therapeutics, Inc. company was founded in 1997 and is based in La Jolla, California. Metabasis Therapeutics, Inc. (Metabasis) is a biopharmaceutical company focused on the discovery development of drugs. The Company’s product pipeline includes product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, which it refer to as its core assets, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer, which it refer to as its non-core assets. All of its product candidates were developed internally using its HepDirect technology. The Company’s pipeline of clinical-stage product candidates also consists of its core asset, MB07803, a product candidate for the treatment of type 2 diabetes, and its non-core assets, pradefovir and MB07133, developed for the treatment of hepatitis B and primary liver cancer, respectively.

Sanofi Pasteur makes vaccines for 20 infectious viral and bacterial diseases, such as diptheria, hepatitis A and B, meningitis, polio, tetanus, and whooping cough. It's also the world's largest maker of the dreaded flu shot, with a 40% market share. The company has more than 15 other vaccines in development, including an HIV vaccine and a combination booster shot to protect against six childhood diseases. Sanofi Pasteur has manufacturing facilities across France and the US, as well as in Argentina, Canada, China, and Thailand. The company is a subsidiary of pharmaceutical giant Sanofi-Aventis.

BioMarin Pharmaceutical Inc. company was founded in 1996 and is headquartered in Novato, California. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The company's approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase.Its clinical development products comprise various product candidates for the treatment of genetic diseases, which include PEG-PAL, an enzyme substitution therapy under Phase I clinical development to treat phenylketonurics, which are not responsive to Kuvan; 6R-BH4, a Phase II clinical development product for the treatment of multiple cardiovascular indications, including sickle cell disease; and GALNS, an enzyme replacement therapy for MPS Type IV or Morquio Syndrome Type A (MPS IV A), a lysosomal storage disease. In addition, the company is conducting preclinical development of various other enzyme product candidates for genetic and other diseases, including a small molecule for the treatment of Duchenne muscular dystrophy. Further, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Europe, and internationally. It has a strategic alliance with Merck Serono S.A. and joint venture with Genzyme Corporation.

XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California. XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohn's disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company's developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited.

BioSyntech is a development-stage company specializing in the creation and development of biotherapeutic thermogels to be used for human tissue repair and therapeutic delivery. The BST-Gels are liquid at room temperature but solidify at human body temperature, and they are classified as medical devices by the FDA and other regulators. Various products in development include BST-CarGel (cartilage repair), BST-InPod (heel cushioning), and BST-DermOn (chronic wound healing). For now, the company makes its money primarily from the sale of Ultrasan, a pure form of chitosan (derived from chitin and is also used in the thermogels), and providing analytical services to support Ultrasan.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.